Factors that affect reopening of blocked portal veins in people with cirrhosis and gastroesophageal varices
Indicators Affecting Portal Vein Thrombosis Recanalization in Cirrhosis With Gastroesophageal Varices
This project looks at past records and follow-up to see which factors are linked with reopening (recanalization) of blocked portal veins in people who have cirrhosis and endoscopy-confirmed gastroesophageal varices.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1500 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Shanghai Zhongshan Hospital Academic / other |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Trial ID | NCT07473375 on ClinicalTrials.gov |
What this trial studies
This retrospective-prospective study at Zhongshan Hospital, Fudan University examines patients with cirrhosis who have endoscopy-confirmed gastroesophageal varices and CT angiography–confirmed portal vein thrombosis (PVT). Researchers will review historical medical records and follow patients prospectively to collect imaging, anticoagulation treatment details, and clinical outcomes to identify factors associated with PVT recanalization. Key exclusions include hepatocellular carcinoma, extrahepatic malignancy, prior liver transplantation or TIPS, cavernous transformation of the portal vein, and missing anticoagulation data. The aim is to improve understanding of diagnosis, follow-up timing, and clinical management related to PVT recanalization.
Who should consider this trial
Good fit: Ideal participants are people with cirrhosis and endoscopy-confirmed gastroesophageal varices who have portal vein thrombosis documented by CTA and complete anticoagulation treatment records, without liver cancer, extrahepatic malignancy, prior transplant or TIPS, or cavernous transformation.
Not a fit: Patients with hepatocellular carcinoma or other extrahepatic cancers, prior liver transplant or TIPS, cavernous transformation of the portal vein, or incomplete anticoagulation information are unlikely to benefit from this study's findings.
Why it matters
Potential benefit: If successful, the findings could help clinicians predict who is likely to reopen blocked portal veins and tailor anticoagulation and follow-up to reduce complications.
How similar studies have performed: Other observational cohorts and anticoagulation studies have reported variable rates of PVT recanalization, so this work builds on existing but not definitive evidence.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:
* diagnosed as cirrhosis and confirmed gastroesophageal varices by endoscopy;
* all patients were diagnosed as PVT by CTA at admission.
Exclusion Criteria:
* patients with hepatocellular carcinoma;
* patients with extrahepatic malignancies;
* history of liver transplantation or TIPS;
* lack of information regarding anticoagulation therapy；
* those with cavernous transformation of the portal vein(CTPV) .
Where this trial is running
Shanghai, Shanghai Municipality
- Shanghai, Shanghai Municipality, China (Recruiting)
Study contacts
- Study coordinator: Siyu Jiang, Dr.
- Email: ksjsy1996926@126.com
- Phone: +86-15121068078
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.